A Brashear

Summary

Affiliation: Wake Forest University School of Medicine
Country: USA

Publications

  1. ncbi Botulinum toxin type A: Exploring new indications
    A Brashear
    Department of Neurology, Wake Forest University Baptist Medical Center, Winston Salem, North Carolina 27157, USA
    Drugs Today (Barc) 46:671-82. 2010
  2. ncbi Spasticity
    Allison Brashear
    Allison Brashear, MD Wake Forest University Health Sciences, Department of Neurology, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Curr Treat Options Neurol 11:153-61. 2009
  3. ncbi The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene
    Allison Brashear
    Department of Neurology, Wake Forest University, Winston Salem, NC 27157, USA
    Brain 130:828-35. 2007
  4. ncbi Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial
    L A Koman
    Department of Orthopaedic Surgery, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1070, USA
    Pediatrics 108:1062-71. 2001
  5. ncbi Clinical comparisons of botulinum neurotoxin formulations
    Allison Brashear
    Department of Neurology, Wake Forest University of Medicine, Winston Salem, NC, USA
    Neurologist 14:289-98. 2008
  6. ncbi Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13
    P L Kramer
    Department of Neurology, Oregon Health Sciences University, Portland 97201, USA
    Ann Neurol 46:176-82. 1999
  7. ncbi Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial
    Allison Brashear
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Arch Phys Med Rehabil 85:705-9. 2004
  8. ncbi Treatment with botulinum toxin type B for upper-limb spasticity
    Allison Brashear
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202 5250, USA
    Arch Phys Med Rehabil 84:103-7. 2003
  9. ncbi Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia
    J Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Neurology 67:2233-5. 2006
  10. ncbi The safety and tolerability of botulinum toxins for the treatment of cervical dystonia
    Allison Brashear
    Indiana University Medical Center, Department of Neurology, CL 291, Indianapolis, IN 46202 5250, USA
    Expert Opin Drug Saf 4:241-9. 2005

Research Grants

  1. Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
    Allison Brashear; Fiscal Year: 2009
  2. Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
    Allison Brashear; Fiscal Year: 2009
  3. Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
    Allison Brashear; Fiscal Year: 2010
  4. Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
    Allison Brashear; Fiscal Year: 2010

Detail Information

Publications13

  1. ncbi Botulinum toxin type A: Exploring new indications
    A Brashear
    Department of Neurology, Wake Forest University Baptist Medical Center, Winston Salem, North Carolina 27157, USA
    Drugs Today (Barc) 46:671-82. 2010
    ....
  2. ncbi Spasticity
    Allison Brashear
    Allison Brashear, MD Wake Forest University Health Sciences, Department of Neurology, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Curr Treat Options Neurol 11:153-61. 2009
    ..Continued communication from all members of the team can assure the best spasticity management plan for the individual patient, but patients need to have realistic expectations about outcome...
  3. ncbi The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene
    Allison Brashear
    Department of Neurology, Wake Forest University, Winston Salem, NC 27157, USA
    Brain 130:828-35. 2007
    ..A positive family history is not required. Genetic testing for the ATP1A3 gene is recommended when abrupt onset, rostrocaudal gradient and prominent bulbar findings are present...
  4. ncbi Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial
    L A Koman
    Department of Orthopaedic Surgery, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1070, USA
    Pediatrics 108:1062-71. 2001
    ..Focal spasticity of the gastrocnemius-soleus muscles causes equinus gait in children with cerebral palsy (CP). Botulinum toxin type A (BTX-A), a neuromuscular blocking agent, reduces muscle tone/overactivity in dystonia, stroke, and CP...
  5. ncbi Clinical comparisons of botulinum neurotoxin formulations
    Allison Brashear
    Department of Neurology, Wake Forest University of Medicine, Winston Salem, NC, USA
    Neurologist 14:289-98. 2008
    ....
  6. ncbi Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13
    P L Kramer
    Department of Neurology, Oregon Health Sciences University, Portland 97201, USA
    Ann Neurol 46:176-82. 1999
    ..Identification of the genetic defect in RDP holds promise for understanding the underlying disease processes of both of these more common diseases...
  7. ncbi Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial
    Allison Brashear
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Arch Phys Med Rehabil 85:705-9. 2004
    ..To determine whether botulinum toxin type B (BTX-B) is effective in controlling upper-limb spasticity...
  8. ncbi Treatment with botulinum toxin type B for upper-limb spasticity
    Allison Brashear
    Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202 5250, USA
    Arch Phys Med Rehabil 84:103-7. 2003
    ..To determine if botulinum toxin type B (MyoBloc) decreases spasticity...
  9. ncbi Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia
    J Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Neurology 67:2233-5. 2006
    ..One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy...
  10. ncbi The safety and tolerability of botulinum toxins for the treatment of cervical dystonia
    Allison Brashear
    Indiana University Medical Center, Department of Neurology, CL 291, Indianapolis, IN 46202 5250, USA
    Expert Opin Drug Saf 4:241-9. 2005
    ....
  11. ncbi Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke
    Allison Brashear
    Department of Neurology, Indiana University School of Medicine, Indianapolis 46202, USA
    N Engl J Med 347:395-400. 2002
    ..Spasticity is a disabling complication of stroke, and it is uncertain whether intramuscular injections of botulinum toxin type A reduce disability in persons with spasticity of the wrist and fingers after a stroke...
  12. ncbi Mutations in the Na+/K+ -ATPase alpha3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism
    Patricia de Carvalho Aguiar
    Department of Molecular Genetics, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Neuron 43:169-75. 2004
    ..This finding implicates the Na+/K+ pump, a crucial protein responsible for the electrochemical gradient across the cell membrane, in dystonia and parkinsonism...
  13. ncbi Rapid-onset dystonia-parkinsonism: a fourth family consistent with linkage to chromosome 19q13
    Jacek Zaremba
    Department of Genetics, Institute of Psychiatry and Neurology, Warsaw, Poland
    Mov Disord 19:1506-10. 2004
    ..By using haplotype analysis, we show that the family is consistent with linkage to markers on chromosome 19q13...

Research Grants5

  1. Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
    Allison Brashear; Fiscal Year: 2009
    ..By defining the role of the ATP1A3 gene mutations in humans and our mouse model, we will impact the study of other neurological diseases, including those with dystonic, neuropsychological, and psychiatric symptoms. ..
  2. Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
    Allison Brashear; Fiscal Year: 2009
    ..By defining the role of the ATP1A3 gene mutations in humans and our mouse model, we will impact the study of other neurological diseases, including those with dystonic, neuropsychological, and psychiatric symptoms. ..
  3. Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
    Allison Brashear; Fiscal Year: 2010
    ..By defining the role of the ATP1A3 gene mutations in humans and our mouse model, we will impact the study of other neurological diseases, including those with dystonic, neuropsychological, and psychiatric symptoms. ..
  4. Clinical, Genetic, And Cellular Consequences of Mutations in Na,K-ATPase ATP1A3
    Allison Brashear; Fiscal Year: 2010
    ..By defining the role of the ATP1A3 gene mutations in humans and our mouse model, we will impact the study of other neurological diseases, including those with dystonic, neuropsychological, and psychiatric symptoms. ..